Senate Panel Wants To Keep Blocking DC From Legal Marijuana Sales, While Pushing Feds To Continue Cannabis Drug Testing Under Rescheduling

Main Hemp Patriot
11 Min Read

A key U.S. Senate committee has released spending bills and attached reports that would keep blocking local officials in Washington, D.C. from legalizing recreational marijuana sales and direct federal officials to continue drug testing safety sensitive workers for cannabis even under rescheduling—while also recognizing the therapeutic potential of psychedelics and noting that Schedule I status undermines research.

The Senate Appropriations Committee on Monday posted the new Fiscal Year 2027 spending legislation and reports, including a measure to fund the Departments of Transportation and Housing and Urban Development (THUD).

The report attached to the THUD bill says that the Trump administration’s move to federally reschedule marijuana should not change cannabis-related drug testing requirements for truck drivers, airline pilots and other safety sensitive workers—saying that doing so could “compromise workforce safety and regulatory consistency.”

“Drug Testing.—The Committee directs the Department of Transportation to maintain current drug testing requirements for cannabis to ensure the continued safety of the Nation’s transportation systems. Cannabis use presents a potential impairment risk for operators responsible for public safety, particularly in aviation, trucking, rail, transit, and pipeline operations, as well as for Federal/ DOT employees that serve in safety-sensitive (e.g., air traffic controllers, safety inspectors, etc.) and security-sensitive (e.g., those with security clearances) positions. In the absence of a scientifically validated threshold correlating cannabis metabolite levels with impairment, relaxing testing requirements could compromise workforce safety and regulatory consistency. The Committee further urges the Department to continue coordinating with HHS and NHTSA on research to develop improved impairment detection methodologies and utilize alternative matrices.”

The separate Financial Services and General Government (FSGG) bill continues a longstanding rider that has prevented local officials in Washington, D.C. from moving forward with plans to legalize and regulate adult-use cannabis sales.

“SEC. 809. (a) None of the Federal funds contained in this Act may be used to enact or carry out any law, rule, or regulation to legalize or otherwise reduce penalties associated with the possession, use, or distribution of any schedule I substance under the Controlled Substances Act (21 U.S.C. 801 et seq.) or any tetrahydrocannabinols derivative.

(b) No funds available for obligation or expenditure by the District of Columbia government under any authority may be used to enact any law, rule, or regulation to legalize or otherwise reduce penalties associated with the possession, use, or distribution of any schedule I substance under the Controlled Substances Act (21 U.S.C. 801 et seq.) or any tetrahydrocannabinols derivative for recreational purposes.”

The report attached to the FSGG bill warns local officials in D.C. about the proximity of dispensaries in the city’s existing medical marijuana program to schools.

“Marijuana Dispensary Proximity to Schools.—The Committee reminds the District that the distribution, manufacturing, and sale of marijuana remains illegal under Federal law, which includes enhanced penalties for such distribution within one thousand feet of a public or private elementary, vocational, or secondary school or public or private college, junior college, or university, or a playground, among other real property where children frequent.”

Another bill to fund the Departments of Labor and Health and Human Services (LaborH) contains a longstanding rider that prevents use of federal funds to promote the legalization of Schedule I drugs.

“SEC. 509. (a) None of the funds made available in this Act may be used for any activity that promotes the legalization of any drug or other substance included in schedule I of the schedules of controlled substances established under section 202 of the Controlled Substances Act except for normal and recognized executive-congressional communications.”

The report attached to the LaborH bill, meanwhile, expresses concerns that Schedule I status for marijuana, psychedelics and other drugs undermines efforts to research them.

“Barriers to Research.—The Committee is concerned that restrictions associated with Schedule I of the Controlled Substances Act effectively limit the amount and type of research that can be conducted on certain Schedule I drugs, especially opioids, psychedelics, marijuana or its component chemicals, and new synthetic drugs and analogs. At a time when we need as much information as possible about these drugs and antidotes for their harmful effects, we should be addressing regulatory and other barriers to conducting this research. The Committee appreciates NIDA’s completion of a report on the barriers to research that result from the classification of drugs and compounds as Schedule I substances including the challenges researchers face as a result of limited access to sources of marijuana, including dispensary products.”

The LaborH report also urges the Centers for Medicare & Medicaid Services (CMS) to issue a report on hospital costs related to marijuana use.

“Marijuana Use.—The Committee recognizes the impact that marijuana-related medical incidents have on hospitals, emergency departments, and clinicians across the United States. The Committee encourages CMS to collect data and report to Congress on Federal and State Medicaid expenditures for hospital services directly linked to marijuana use.”

It additionally contains several separate sections focused on the need to research the medical benefits of psychedelics.

“Psychedelic Research.—The Committee recognizes the increased interest and need to study psychedelics and their potential therapeutic effects. The Committee encourages NIH to expand its current research agenda across its Institutes and Centers also encourages NIH to work with FDA in developing and supporting public-private collaborations to advance all forms of psychedelic research for therapeutic purposes.”

“Neuroplastogen Research for Substance Use Disorders.—The Committee recognizes the increased interest and need to study neuroplastogens, including psilocybin, ibogaine, 5–MeO–DMT, lysergic acid diethylamide, and MDMA, and their potential therapeutic effects for substance use disorders, including methamphetamine use disorder, opioid use disorder, cocaine use disorder, stimulant use disorder, and co-occurring mental health and substance use disorders. The Committee encourages NIDA to prioritize this research, including collaborating with NIMH, NIAAA, and FDA to develop new treatments for substance use disorders and mental health disorders.”

“Emerging Mental Health and Substance Use Treatment Workforce and Training.—The Committee recognizes that several emerging mental health and substance use treatments-including psychedelic therapies, neuroplastogens, accelerated transcranial magnetic stimulation [TMS], and other neuromodulation devices and protocols-provide a potential pathway to reducing the burden of mental illness and substance use disorders. The Committee encourages SAMHSA to assess the behavioral health workforce and training needs for delivery of these emerging treatments and, as appropriate, to assess workforce preparedness and training needs associated with emerging behavioral health treatments, including therapies that have been approved or cleared by the FDA. The Committee also encourages SAMHSA to give special consideration to ensuring workforce preparedness in rural and exurban areas and regions with a high concentration of veterans and Medicaid and/or Medicare-eligible patients.”

—
Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.


Learn more about our marijuana bill tracker and become a supporter on Patreon to get access.
—

Finally, a report attached to a separate bill to fund the State Department and foreign operations has a provision directing the secretary of state to report to Congress about Chinese-linked illegal cannabis cultivation operations within the U.S.

“Chinese Criminal Syndicates and Marijuana Grows.—The Secretary of State, in consultation with the relevant heads of other Federal agencies, shall submit a report to the appropriate congressional committees, the Senate Select Committee on Intelligence, and the House Permanent Select Committee on Intelligence on Chinese criminal syndicates or nationals who may be directly or indirectly involved in marijuana grows and money laundering operations in the United States, including in Maine, California, and Oregon. The information should include, as relevant, officials of the Government of the PRC and syndicates operating in Southeast Asia.”

Last week, the Senate Appropriations Committee released other funding bills and reports directing federal agencies to consider medical marijuana as an opioid alternative as well as the therapeutic benefits of psychedelics—while also encouraging hemp cultivar and germplasm development and additionally raising concerns about cannabinoid-infused foods.

Another group of bills and reports separately posted by the panel propose to continue a current rider in federal law that shields state medical marijuana programs from federal interference—while also declining to join the House in supporting a separate provision that would block federal officials from advancing the Trump administration’s federal cannabis rescheduling proposal.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.

Become a patron at Patreon!

-56 metal pipes for smoke weed

Smoking Metal Stainless Steel Mesh Pipe Screen Filters

Original price was: $15.99.Current price is: $6.99.
Sale! Creative Cigarette-Shaped Metal Pipe

Creative Cigarette-Shaped Metal Pipe

Price range: $6.99 through $12.99 This product has multiple variants. The options may be chosen on the product page
-50 metal pipes for smoke weed

Mini Multicolor Baseball Bat Portable Metal Pipe

Original price was: $19.99.Current price is: $9.99.
-50 metal pipes for smoke weed

Portable Water Smoking Filtration Pipe Bong

Original price was: $19.99.Current price is: $9.99.


-50 metal pipes for smoke weed

Portable Water Smoking Filtration Pipe Bong

Original price was: $19.99.Current price is: $9.99.
Sale! glass bongs

Patriots Hemp Double Hose Glass Hookah Large Bowl Smoking Water Pipe Bong

Original price was: $39.99.Current price is: $24.99. This product has multiple variants. The options may be chosen on the product page
-25 bongs and pipes for smoking weed

Mini Smoking Metal Acrylic Water Pipe

Original price was: $19.99.Current price is: $14.99.
Sale! bongs and pipes for smoking weed

Multi-Colored Water Smoking Pipe Bong

Original price was: $19.99.Current price is: $14.99. This product has multiple variants. The options may be chosen on the product page




Share This Article
Leave a Comment

Leave a Reply